Rivulet (AVOI) $10M sale fails to solve liquidity crisis; going-concern flagged

Rivulet Entertainment, Inc. (OTCBB: AVOI)

Quick take: the company completed a reverse merger (July 2024), ramped production and sold a film for $10,000,000 during the nine months ended March 31, 2025 - but that sale essentially consumed the related capitalized film costs and the business is facing acute liquidity, control and debt-pressure issues. Management discloses substantial doubt about the company's ability to continue as a going concern.

Key facts & statistics (as reported)
* Cash: $100,633 (March 31, 2025)
* Accounts receivable: $2,000,000 (March 31, 2025) - subsequently collected $2,000,000 per subsequent events
* Total assets: $20,724,342 (March 31, 2025)
* Film costs (noncurrent): $13,849,675 (March 31, 2025)
* Total current liabilities: $25,486,849 (March 31, 2025)
* Total liabilities: $25,486,849 (March 31, 2025)
* Shareholders' deficit: ($4,762,507) (March 31, 2025)
* Notes payable (total): $18,337,509 (March 31, 2025) - non-current portion $0 (all classified current)
* Related party loans, current: $2,880,000
* Revenues: $10,000,000 for nine months ended March 31, 2025 (no revenue in comparable 2024 period)
* Production cost amortization: $10,468,247 (nine months ended March 31, 2025)
* General & administrative expense: $3,074,162 (nine months ended March 31, 2025)
* Net loss: ($4,181,134) (nine months ended March 31, 2025); quarterly loss ($554,539) for Q3
* Net cash used in operating activities: ($9,253,018) (nine months ended March 31, 2025)
* Shares outstanding: 109,695,876 (as of Sept 10, 2025)
* Defaults / arrearage: ~$353,000 principal in default; total arrearage ≈ $420,000 reported
* Subsequent events: collected $2.0M receivable; ~$2.3M paid on notes; issued ~$2.7M new notes at 10-15% interest

What's happening inside the company
* Post-merger integration: Rivulet completed a reverse merger and recognized debt forgiveness (~$8,077,965) and recapitalization adjustments. Management expanded production activities and added multiple production subsidiaries.
* Film production financing: the company relies heavily on short-term notes, tax-credit assignment loans and a $3.5M credit facility (drawn). It capitalized large film costs ($13.85M) and amortized $10.47M when a film was sold.
* Liquidity pressure: cash is minimal, working capital is deeply negative, operating cash burn is large and management explicitly flags going-concern risk. Several short-term notes are in technical default.

Income statement - positives
* Generated $10,000,000 revenue from a film sale in the period (a material one-off monetization).
* Film cost amortization is non-cash (capitalized interest partly offsets cash impact) - offers accounting transparency on cost recovery versus cash flow timing.

Income statement - negatives
* Net loss of ($4,181,134) for nine months despite the $10M sale - because production cost amortization ($10,468,247) plus G&A ($3,074,162) and interest turned the period into a loss.
* Heavy G&A and participation costs: participation expense of $1,995,058 and total G&A of $3.07M materially reduced profitability.
* Interest expense large: interest expense $640,837 (nine months) driven by increased short-term borrowing; cash interest paid $590,265 (nine months).
* Results show reliance on one-off film sales rather than recurring revenue; the sold film "does not expect to generate additional revenues" per the filing.

Risks / red flags for investors
* Substantial going-concern doubt explicitly disclosed.
* Negative working capital (~$22.6M per MD&A) and shareholders' deficit ($4.76M).
* Multiple short-term notes, defaults (~$353k principal) and high effective interest rates (10-20% on many notes).
* Material weaknesses in internal controls (lack of segregation of duties and formal documentation).
* Concentration risk: single customer AR ($2.0M) tied to the $10M sale (though subsequently collected).

Bottom line / near-term outlook
Rivulet (OTCBB: AVOI) has demonstrated the ability to monetize content (a $10M sale) but remains highly leveraged, cash-poor and dependent on additional financing and film-rights sales to survive. The company has taken near-term steps (collections, debt repayments and new note issuances) after March 31, 2025, but the structural risks - negative working capital, defaults, and control weaknesses - make this a high-risk situation for equity holders. Any improvement depends on successful, timely monetization of film assets and disciplined refinancing of short‑term debt.

If you want, I can turn this into a one-page investor memo with a short valuation-sensitive scenario (best / base / worst) and checklist of events to watch.